Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Radius Recycling, Inc. - Class A (RDUS)
Last radius recycling, inc. - class a earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.radiuspharm.com
Company Research
Source: GlobeNewswire
-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017- -Median PFS was 5.4 months and Clinical Benefit Rate at 24 weeks was 47.4% - -38% of study patients previously received fulvestrant; 40% received palbociclib or other CDK 4/6 inhibitor; 50% had an ESR1 mutation- -10 of the 40 patients remain on treatment as of the cutoff date- -Investor Webcast today at 8:00 pm CT- WALTHAM, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation
Show less
Read more
Impact Snapshot
Event Time:
RDUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDUS alerts
High impacting Radius Recycling, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RDUS
News
- Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Accesswire
- Radius Recycling, Inc. (NASDAQ: RDUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Radius Recycling Reports Second Quarter Fiscal 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Radius Recycling Reports Second Quarter Fiscal 2024 Financial ResultsGlobeNewswire
- Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date [Yahoo! Finance]Yahoo! Finance